Joseph Patrick McEvoy

Journal Article JAMA · May 21, 2014 IMPORTANCE: Long-acting injectable antipsychotics are used to reduce medication nonadherence and relapse in schizophrenia-spectrum disorders. The relative effectiveness of long-acting injectable versions of second-generation and older antipsychotics has no ... Full text Link to item Cite

Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.

Journal Article Am J Psychiatry · September 2013 OBJECTIVE: The purpose of this study was to determine whether metformin promotes weight loss in overweight outpatients with chronic schizophrenia or schizoaffective disorder. METHOD: In a double-blind study, 148 clinically stable, overweight (body mass ind ... Full text Link to item Cite

High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.

Journal Article J Clin Psychopharmacol · August 2013 Uncontrolled studies have suggested that increasing the dose of ziprasidone above the standard maximum daily dose of 160 mg may be more effective for some patients with schizophrenia. To test this hypothesis, we conducted an 8-week, placebo-controlled, fix ... Full text Link to item Cite

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.

Journal Article Neuropsychopharmacology · June 2013 Schizophrenia is associated with extensive neurocognitive and behavioral impairments. Studies indicate that N-acetylaspartate (NAA), a marker of neuronal integrity, and choline, a marker of cell membrane turnover and white matter integrity, may be altered ... Full text Link to item Cite

Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.

Journal Article Schizophr Res · May 2013 PURPOSE: This study examined the clinical significance of switching from olanzapine, quetiapine, or risperidone to aripiprazole by examining changes in predicted risk of cardiovascular disease (CVD) according to the Framingham Risk Score (FRS) and metaboli ... Full text Link to item Cite

Persistent infection with neurotropic herpes viruses and cognitive impairment.

Journal Article Psychol Med · May 2013 BACKGROUND: Herpes virus infections can cause cognitive impairment during and after acute encephalitis. Although chronic, latent/persistent infection is considered to be relatively benign, some studies have documented cognitive impairment in exposed person ... Full text Link to item Cite

Principal components of heritability from neurocognitive domains differ between families with schizophrenia and control subjects.

Journal Article Schizophr Bull · March 2013 OBJECTIVE: Various measures of neurocognitive function show mean differences among individuals with schizophrenia (SZ), their relatives, and population controls. We use eigenvector transformations that maximize heritability of multiple neurocognitive measu ... Full text Link to item Cite

Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.

Journal Article J Clin Psychiatry · February 2013 OBJECTIVE: To examine the effectiveness of switching patients to lurasidone using 3 different dosing strategies. METHOD: Adults with DSM-IV-defined schizophrenia or schizoaffective disorder in a nonacute phase of illness were randomized to 1 of 3 lurasidon ... Full text Link to item Cite

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study

Journal Article CNS Spectrums · 2013 Objective: To evaluate the long-term safety and tolerability of lurasidone in schizophrenia and schizoaffective disorder patients switched to lurasidone. Method: Patients in this multicenter, 6-month open-label, flexible-dose, extension study had completed ... Full text Cite

Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics.

Journal Article PLoS One · 2013 There is a critical need for mapping early metabolic changes in schizophrenia to capture failures in regulation of biochemical pathways and networks. This information could provide valuable insights about disease mechanisms, trajectory of disease progressi ... Full text Link to item Cite

Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure.

Journal Article Schizophr Bull · November 2012 BACKGROUND: Genome-wide association studies (GWAS) implicate single nucleotide polymorphisms (SNPs) on chromosome 6p21.3-22.1, the human leukocyte antigen (HLA) region, as common risk factors for schizophrenia (SZ). Other studies implicate viral and protoz ... Full text Link to item Cite

Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects.

Journal Article Clin Schizophr Relat Psychoses · October 2012 The initial tailoring of antipsychotic medication for an individual experiencing a first episode of psychosis (FEP) is a critical empirical process with potentially far-reaching consequences. This article reviews the results of randomized treatment trials ... Full text Link to item Cite

Religious coping and quality of life among individuals living with schizophrenia.

Journal Article Psychiatr Serv · October 1, 2012 OBJECTIVE This study investigated the relationship between positive and negative religious coping and quality of life among outpatients with schizophrenia. METHODS Interviews were conducted with 63 adults in the southeastern United States. Religious coping ... Full text Link to item Cite

Impaired plasmalogens in patients with schizophrenia.

Journal Article Psychiatry Res · August 15, 2012 Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids betw ... Full text Link to item Cite

Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia.

Journal Article Am J Hum Genet · August 10, 2012 Schizophrenia is a severe psychiatric disorder with strong heritability and marked heterogeneity in symptoms, course, and treatment response. There is strong interest in identifying genetic risk factors that can help to elucidate the pathophysiology and th ... Full text Link to item Cite

Heritability of functioning in families with schizophrenia in relation to neurocognition.

Journal Article Schizophr Res · August 2012 UNLABELLED: The role of daily functioning is an integral part of the schizophrenia (SZ) phenotype and deficits in this trait appear to be present in both affected persons and some unaffected relatives; hence we have examined its heritability in our cohort ... Full text Link to item Cite

Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.

Journal Article J Clin Psychiatry · May 2012 OBJECTIVE: This multisite randomized trial addressed risks and benefits of staying on long-acting injectable haloperidol or fluphenazine versus switching to long-acting injectable risperidone microspheres. METHOD: From December 2004 through March 2008, adu ... Full text Link to item Cite

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

Journal Article Schizophr Res · April 2012 BACKGROUND: Cognitive dysfunction is a key predictor of functional disability in schizophrenia. Davunetide (AL-108, NAP) is an intranasally administered peptide currently being developed for treatment of Alzheimer's disease and related disorders. This stud ... Full text Link to item Cite

Associations between purine metabolites and clinical symptoms in schizophrenia.

Journal Article PLoS One · 2012 BACKGROUND: The antioxidant defense system, which is known to be dysregulated in schizophrenia, is closely linked to the dynamics of purine pathway. Thus, alterations in the homeostatic balance in the purine pathway may be involved in the pathophysiology o ... Full text Link to item Cite

Criminal justice system involvement among people with schizophrenia.

Journal Article Community Ment Health J · December 2011 There is growing concern that people with schizophrenia and other severe mental illnesses are increasingly at risk for unnecessary criminal justice system (CJS) involvement. There has been limited examination, however, of which individual characteristics p ... Full text Link to item Cite

Substance use and schizophrenia: adverse correlates in the CATIE study sample.

Journal Article Schizophr Res · November 2011 OBJECTIVE: This study examined the relationship between severity of illicit substance use at the time of study entry in a sample of patients diagnosed with schizophrenia and 18-month longitudinal outcomes, including psychopathology, depression, neurocognit ... Full text Link to item Cite

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Journal Article Am J Psychiatry · September 2011 OBJECTIVE: The authors conducted a multisite randomized controlled trial examining the strategy of switching from olanzapine, quetiapine, or risperidone to aripiprazole to ameliorate metabolic risk factors for cardiovascular disease. METHOD: Patients with ... Full text Link to item Cite

Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.

Journal Article Schizophr Res · August 2011 OBJECTIVE: Research participants must have adequate consent-related abilities to provide informed consent at the time of study enrollment. We sought to determine if research participants with schizophrenia maintain adequate consent-related abilities during ... Full text Link to item Cite

3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.

Journal Article Int J Neuropsychopharmacol · July 2011 One branch of the tryptophan catabolic cascade is the kynurenine pathway, which produces neurotoxic [3-hydroxykynurenine (3-OHKY), quinolinic acid] and neuroinhibitory (kynurenic acid) compounds. Kynurenic acid acts as a competitive antagonist at the glyci ... Full text Link to item Cite

Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

Journal Article Am J Psychiatry · July 2011 OBJECTIVE: This randomized trial addressed the risks and benefits of staying on antipsychotic polypharmacy or switching to monotherapy. METHOD: Adult outpatients with schizophrenia taking two antipsychotics (127 participants across 19 sites) were randomly ... Full text Link to item Cite

Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.

Journal Article Psychiatry Res · May 15, 2011 Early response to antipsychotic medication has been shown to accurately predict later response to continued use of the same treatment in patients with chronic schizophrenia. This study examines whether this predictive pattern exists for patients with first ... Full text Link to item Cite

Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking.

Journal Article Evid Based Ment Health · May 2011 Full text Link to item Cite

The association between weight change and symptom reduction in the CATIE schizophrenia trial.

Journal Article Schizophr Res · May 2011 BACKGROUND: Weight gain and changes in metabolic indicators associated with some antipsychotics may be related to symptom improvement and thus an unavoidable correlate of clinical benefit. METHODS: Data from the CATIE schizophrenia trial comparing the effe ... Full text Link to item Cite

Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.

Journal Article J Clin Psychiatry · March 2011 OBJECTIVE: We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD. METHOD: This analysis compared 200 patients with DSM-IV-defined schizophrenia and TD and 997 patients wi ... Full text Link to item Cite

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.

Journal Article Biol Psychiatry · March 1, 2011 BACKGROUND: In a previous pilot study, MK-0777--a γ-aminobutyric acid (GABA)(A) α2/α3 partial agonist--was reported to improve delayed memory and cognitive measures of prefrontal cortical function in people with schizophrenia. The current study was designe ... Full text Link to item Cite

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.

Journal Article Mol Psychiatry · March 2011 Understanding individual differences in the susceptibility to metabolic side effects as a response to antipsychotic therapy is essential to optimize the treatment of schizophrenia. Here, we perform genomewide association studies (GWAS) to search for geneti ... Full text Link to item Cite

Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.

Journal Article Neuropsychopharmacology · February 2011 Neurocognitive deficits are a core feature of schizophrenia and, therefore, represent potentially critical outcome variables for assessing antipsychotic treatment response. We performed genome-wide association studies (GWAS) with 492K single nucleotide pol ... Full text Link to item Cite

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.

Journal Article J Clin Psychiatry · January 2011 BACKGROUND: According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these m ... Full text Link to item Cite

Response to Baandrup letter

Journal Article American Journal of Psychiatry · 2011 Full text Cite

Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population.

Journal Article Schizophr Bull · January 2011 Celiac disease (CD) and schizophrenia have approximately the same prevalence, but epidemiologic data show higher prevalence of CD among schizophrenia patients. The reason for this higher co-occurrence is not known, but the clinical knowledge about the pres ... Full text Link to item Cite

Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.

Journal Article Mol Psychiatry · September 2010 Schizophrenia is characterized by complex and dynamically interacting perturbations in multiple neurochemical systems. In the past, evidence for these alterations has been collected piecemeal, limiting our understanding of the interactions among relevant b ... Full text Link to item Cite

Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia.

Journal Article PLoS One · March 3, 2010 BACKGROUND: Purine catabolism may be an unappreciated, but important component of the homeostatic response of mitochondria to oxidant stress. Accumulating evidence suggests a pivotal role of oxidative stress in schizophrenia pathology. METHODOLOGY/PRINCIPA ... Full text Open Access Link to item Cite

First- and second-generation antipsychotics.

Journal Article Can J Psychiatry · March 2010 Full text Link to item Cite

A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial.

Journal Article Am J Med Genet B Neuropsychiatr Genet · January 5, 2010 Tardive dyskinesia (TD) is a movement disorder characterized by involuntary oro-facial, limb, and truncal movements. As a genetic basis for inter-individual variation is assumed, there have been a sizeable number of candidate gene studies. All subjects met ... Full text Link to item Cite

Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.

Journal Article Biol Psychiatry · December 1, 2009 BACKGROUND: C-reactive protein (CRP), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin are systemic inflammatory markers (IM) that positively correlate with cardiovascular (CV) risk. Despite the known C ... Full text Link to item Cite

Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.

Journal Article Schizophr Res · August 2009 BACKGROUND: One of the major challenges in the design of double-blind flexible-dosing clinical trials comparing active drugs is the selection of dosing regimens that are equivalent across drugs. This study uses data from the CATIE schizophrenia trial to ev ... Full text Link to item Cite

Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.

Journal Article Eur J Hum Genet · July 2009 The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Phase 1 Schizophrenia trial compared the effectiveness of one typical and four atypical antipsychotic medications. Although trials such as CATIE present important opportunities for pha ... Full text Link to item Cite

Convergent patterns of association between phenylalanine hydroxylase variants and schizophrenia in four independent samples.

Journal Article Am J Med Genet B Neuropsychiatr Genet · June 5, 2009 Recessive mutations in the phenylalanine hydroxylase (PAH) gene predispose to phenylketonuria (PKU) in conjunction with dietary exposure to phenylalanine. Previous studies have suggested PAH variations could confer risk for schizophrenia, but comprehensive ... Full text Link to item Cite

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

Journal Article Schizophr Res · June 2009 OBJECTIVE: To further define the metabolic profiles of second-generation antipsychotics during the treatment of young patients with early psychosis, with a view to better inform prescribing clinicians. METHOD: Weight, body mass index (BMI), glucose, and se ... Full text Link to item Cite

Time-lapse mapping of cortical changes in schizophrenia with different treatments.

Journal Article Cereb Cortex · May 2009 Using time-lapse maps, we visualized the dynamics of schizophrenia progression, revealing spreading cortical changes that depend on the type of antipsychotic treatment. Dynamic, 4-dimensional models of disease progression were created from 4 repeated high- ... Full text Link to item Cite

Linkage analysis of schizophrenia in African-American families.

Journal Article Schizophr Res · April 2009 While many studies have sought a window into the genetics of schizophrenia, few have focused on African-American families. An exception is the Project among African-Americans to Explore Risks for Schizophrenia (PAARTNERS), which seeks to identify novel and ... Full text Link to item Cite

Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.

Journal Article Schizophr Bull · March 2009 BACKGROUND: We evaluated the cross-sectional and longitudinal association of measures of both insight and attitudes toward medication to outcomes that included psychopathology and community functioning. METHODS: Clinical Antipsychotic Trial of Intervention ... Full text Link to item Cite

A genome-wide investigation of SNPs and CNVs in schizophrenia.

Journal Article PLoS Genet · February 2009 We report a genome-wide assessment of single nucleotide polymorphisms (SNPs) and copy number variants (CNVs) in schizophrenia. We investigated SNPs using 871 patients and 863 controls, following up the top hits in four independent cohorts comprising 1,460 ... Full text Link to item Cite

Much ado about small differences.

Journal Article World Psychiatry · February 2009 Full text Link to item Cite

Results of phase 3 of the CATIE schizophrenia trial.

Journal Article Schizophr Res · January 2009 OBJECTIVE: The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study examined the comparative effectiveness of antipsychotic treatments for individuals with chronic schizophrenia. Patients who had discontinued antipsychotic treatment in ... Full text Link to item Cite

The impact of obesity on health care costs among persons with schizophrenia.

Journal Article Gen Hosp Psychiatry · 2009 BACKGROUND: Obesity is the second leading cause of preventable death in the United States and is twice as common among individuals with schizophrenia as the general population. METHODS: Data from the Clinical Antipsychotic Trials of Intervention Effectiven ... Full text Link to item Cite

Much ado about small differences

Journal Article Postepy Psychiatrii i Neurologii · 2009 Cite

The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

Journal Article J Clin Psychiatry · 2009 OBJECTIVES: Poor adherence to medication treatment can have devastating consequences for patients with mental illness. The goal of this project was to develop recommendations for addressing adherence problems to improve patient outcomes. METHODS: The edito ... Link to item Cite

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol (American Journal of Psychiatry (2003) 160, (1396-1404))

Journal Article American Journal of Psychiatry · 2009 Cite

Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.

Journal Article Schizophr Res · January 2009 PURPOSE: Previous analysis of data from CATIE showed that patients randomly assigned to switch to a new medication were more likely to discontinue study drug than those who stayed on the medication they had been taking prior to randomization. This study ad ... Full text Link to item Cite

Antipsychotic Drugs

Journal Article · January 1, 2009 All antipsychotic drugs decrease dopamine neurotransmission. The conventional neuroleptic drugs block dopamine D2 receptors, leading to a gradual reduction of acute psychotic features and the prevention of relapse; they produce coarse neurological side eff ... Full text Cite

Extrapyramidal side-effects of antipsychotics in a randomised trial.

Journal Article Br J Psychiatry · October 2008 BACKGROUND: There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs. AIMS: To compare the incidence of treatment-emergent EPS between second-generation antipsychotics and p ... Full text Link to item Cite

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.

Journal Article Schizophr Res · October 2008 OBJECTIVE: Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to examine effects of different antipsychotic treatments on estimates of 10-year coronary heart disease (CHD ... Full text Link to item Cite

Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study.

Journal Article Genet Med · October 2008 PURPOSE: To evaluate systematically in real clinical settings whether functional genetic variations in drug metabolizing enzymes influence optimized doses, efficacy, and safety of antipsychotic medications. METHODS: DNA was collected from 750 patients with ... Full text Link to item Cite

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

Journal Article Schizophr Res · August 2008 BACKGROUND: Recent literature documents a stronger association between nonfasting triglycerides (TG) and cardiovascular risk compared to fasting TG. Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in p ... Full text Link to item Cite

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.

Journal Article Br J Psychiatry · July 2008 BACKGROUND: Violence is an uncommon but significant problem associated with schizophrenia. AIMS: To compare antipsychotic medications in reducing violence among patients with schizophrenia over 6 months, identify prospective predictors of violence and exam ... Full text Link to item Cite

What CATIE found: results from the schizophrenia trial.

Journal Article Psychiatr Serv · May 2008 The authors provide an overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) sponsored by the National Institute of Mental Health. CATIE was designed to compare a proxy first-generation antipsychotic, perphenazine, to several ... Full text Link to item Cite

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.

Journal Article Schizophr Res · April 2008 BACKGROUND: The metabolic syndrome (MS) is associated with increased risk for diabetes mellitus and coronary heart disease, and is highly prevalent among schizophrenia patients. Given concerns over antipsychotic metabolic effects, this analysis explored MS ... Full text Link to item Cite

Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.

Journal Article J Behav Health Serv Res · April 2008 Employment has been increasingly recognized as an important goal for individuals with schizophrenia. Previous research has shown mixed results on the relationship of specific antipsychotic medications to employment outcomes, with some studies finding great ... Full text Link to item Cite

The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.

Journal Article Schizophr Res · March 2008 OBJECTIVE: This double-blind study compared a second generation (atypical) antipsychotic drugs compared to a representative older agent for patients with schizophrenia who use or avoid illicit substances. METHODS: Schizophrenic subjects were recruited at 5 ... Full text Link to item Cite

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.

Journal Article J Int Neuropsychol Soc · March 2008 Efficient and reliable assessments of cognitive treatment effects are essential for the comparative evaluation of procognitive effects of pharmacologic therapies. Yet, no studies have addressed the sensitivity and efficiency with which neurocognitive batte ... Full text Link to item Cite

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

Journal Article Schizophrenia Research · 2008 Cite

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study

Journal Article Journal of Clinical Psychopharmacology · 2008 The objective of this study was to assess the dose-response relationship of standard and higher doses of olanzapine in a randomized, double-blind, 8-week, fixed-dose study comparing olanzapine 10 (n = 199), 20 (n = 200), and 40 mg/d (n = 200) for patients ... Full text Cite

Functional outcomes in schizophrenia.

Journal Article J Clin Psychiatry · 2008 A recent expert panel has proposed consensus criteria for remission in schizophrenia. They distinguished remission from recovery, noting that the latter outcome was likely to require not only remission of symptoms, but also improvement in cognitive and psy ... Link to item Cite

Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.

Journal Article J Clin Psychiatry · January 2008 OBJECTIVE: To evaluate predictors of treatment discontinuation against medical advice and poor medication adherence among first-episode patients treated with olanzapine, quetiapine, or risperidone. METHOD: First-episode patients with schizophrenia, schizop ... Full text Link to item Cite

Issues in the Design and Conductance of Clinical Trials

Journal Article · January 1, 2008 Clinical trials are conducted to determine the therapeutic efficacy, effectiveness, safety, and tolerability of interventions for clinical disorders. The best clinical trials are designed to do this efficiently with minimal potential for bias. This chapter ... Full text Cite

Dr. Keefe and colleagues reply

Journal Article American Journal of Psychiatry · December 1, 2007 Full text Cite

A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.

Journal Article J Psychiatr Res · December 2007 This double-blind, multicenter study aimed to investigate the efficacy and safety of aripiprazole 10, 15 or 20 mg/day versus placebo. Patients requiring inpatient hospitalization for acute exacerbation of schizophrenia were randomized to once-daily aripipr ... Full text Link to item Cite

Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH schizophrenia trials network study

Journal Article Clinical Schizophrenia and Related Psychoses · December 1, 2007 Because of growing concern about the physical health status of persons with schizophrenia and uncertainty regarding optimal strategies to manage metabolic side effects of antipsychotic drugs that increase the risk of cardiovascular disease, we developed a ... Full text Cite

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

Journal Article J Clin Psychiatry · November 2007 BACKGROUND: A panel of academic psychiatrists and pharmacists, clinicians from the Texas public mental health system, advocates, and consumers met in June 2006 in Dallas, Tex., to review recent evidence in the pharmacologic treatment of schizophrenia. The ... Full text Link to item Cite

Metabolomic mapping of atypical antipsychotic effects in schizophrenia.

Journal Article Mol Psychiatry · October 2007 Schizophrenia is associated with impairments in neurotransmitter systems and changes in neuronal membrane phospholipids. Several atypical antipsychotic drugs induce weight gain and hypertriglyceridemia. To date, there has not been a comprehensive evaluatio ... Full text Link to item Cite

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Journal Article Am J Psychiatry · July 2007 OBJECTIVE: The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis. METHOD: In a 52-week double-blind, multicenter study, 400 patients early in the course of psychotic ... Full text Link to item Cite

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.

Journal Article Am J Psychiatry · July 2007 OBJECTIVE: This 52-week randomized, double-blind, flexible-dose, multicenter study evaluated the overall effectiveness (as measured by treatment discontinuation rates) of olanzapine, quetiapine, and risperidone in patients early in the course of psychotic ... Full text Link to item Cite

Determining when impairment constitutes incapacity for informed consent in schizophrenia research.

Journal Article Br J Psychiatry · July 2007 BACKGROUND: Although people with schizophrenia display impaired abilities for consent, it is not known how much impairment constitutes incapacity. AIMS: To assess a method for determining the categorical capacity status of potential participants in schizop ... Full text Link to item Cite

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Journal Article Arch Gen Psychiatry · June 2007 CONTEXT: Neurocognitive impairment in schizophrenia is severe and is an important predictor of functional outcome. The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively d ... Full text Link to item Cite

Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial.

Journal Article Expert Rev Pharmacoecon Outcomes Res · April 2007 The cost-effectiveness component of the 18-month CATIE trial of schizophrenia pharmacotherapy (n = 1460) showed that the first-generation antipsychotic perphenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, ... Full text Link to item Cite

The importance of early treatment of schizophrenia.

Journal Article Behav Healthc · April 2007 It is extremely important to treat schizophrenia as soon as possible after the onset. With delay in effective treatment, patients may be at increased risk for brain volume loss with adverse implications for long-term treatment outcomes. Providers should no ... Link to item Cite

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Journal Article Am J Psychiatry · March 2007 OBJECTIVE: The relative effectiveness of newly started antipsychotic drugs for individuals with schizophrenia may depend on multiple factors, including each patient's previous treatment response and the reason for a new medication trial. This randomized, d ... Full text Link to item Cite

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

Journal Article Am J Psychiatry · March 2007 OBJECTIVE: This study examined the relative effects of the second-generation antipsychotic drugs and an older representative agent on psychosocial functioning in patients with chronic schizophrenia. METHOD: Consenting patients were enrolled in the NIMH Cli ... Full text Link to item Cite

Erratum to "Project among African-Americans to explore risks for schizophrenia (PAARTNERS): Recruitment and assessment methods" [Schizophrenia Research 87 (1-3) (2006) 32-44] (DOI:10.1016/j.schres.2006.06.027)

Journal Article Schizophrenia Research · February 1, 2007 Full text Cite

Dr. Rosenheck and colleagues reply [2]

Journal Article American Journal of Psychiatry · January 1, 2007 Full text Cite

The costs of schizophrenia.

Journal Article J Clin Psychiatry · 2007 Reasonably accurate approximations of the financial costs of schizophrenia are the foundation for making judgments about the socioeconomic impact of the disorder and the cost-effectiveness of treatment modalities. The financial costs of schizophrenia to so ... Link to item Cite

Catatonic coma with profound bradycardia.

Journal Article Psychosomatics · 2007 Catatonia may be monosymptomatic at presentation, with stupor or coma as the cardinal and only manifestation. A case of catatonic coma with profound bradycardia is presented to help clinicians recognize this entity and include catatonia in the differential ... Full text Link to item Cite

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Journal Article Am J Psychiatry · December 2006 BACKGROUND: Second-generation antipsychotics have largely replaced first-generation antipsychotics for the treatment of schizophrenia, but a large-scale cost/effectiveness analysis has not been attempted. METHOD: Patients with schizophrenia (N=1,493) were ... Full text Link to item Cite

Insight in first-episode psychosis.

Journal Article Psychol Med · October 2006 BACKGROUND: We report here a study examining the relationships between insight and psychopathology, cognitive performance, brain volume and co-morbid depression in 251 patients experiencing a first episode of psychosis, who were then randomly assigned to 2 ... Full text Link to item Cite

Project among African-Americans to explore risks for schizophrenia (PAARTNERS): recruitment and assessment methods.

Journal Article Schizophr Res · October 2006 The Project among African-Americans to Explore Risks for Schizophrenia (PAARTNERS) is a multi-site, NIMH-funded study that seeks to identify genetic polymorphisms that confer susceptibility to schizophrenia among African-Americans by linkage mapping and ta ... Full text Link to item Cite

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

Journal Article Neuropsychopharmacology · September 2006 Neurocognition is moderately to severely impaired in patients with schizophrenia. However, the factor structure of the various neurocognitive deficits, the relationship with symptoms and other variables, and the minimum amount of testing required to determ ... Full text Link to item Cite

Olanzapine and haloperidol in first episode psychosis: two-year data.

Journal Article Schizophr Res · September 2006 Few studies have assessed the comparative efficacy and safety of atypical and typical antipsychotic medications in patients within their first episode of psychosis. This study examined the effectiveness of the atypical antipsychotic olanzapine and the typi ... Full text Link to item Cite

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.

Journal Article Schizophr Res · September 2006 UNLABELLED: Persons diagnosed with schizophrenia have higher morbidity and mortality rates from cardiovascular disease, yet often have limited access to appropriate primary care screening or treatment. Metabolic disorders such as diabetes, hyperlipidemia a ... Full text Link to item Cite

Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia.

Journal Article Psychiatr Serv · August 2006 OBJECTIVE: This cross-sectional study aimed to evaluate the interrelationships of psychiatric symptom severity, medical comorbidity, and psychosocial functioning in a sample of patients with schizophrenia by utilizing the baseline data from the Clinical An ... Full text Link to item Cite

Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study.

Journal Article Psychiatr Serv · August 2006 OBJECTIVE: This study examined the relationship between substance use and psychosocial functioning in schizophrenia. METHODS: Participants were enrolled in the Clinical Antipsychotic Trials of Intervention Effectiveness. This study used baseline assessment ... Full text Link to item Cite

An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.

Journal Article CNS Spectr · July 2006 Full text Link to item Cite

A national study of violent behavior in persons with schizophrenia.

Journal Article Arch Gen Psychiatry · May 2006 CONTEXT: Violent behavior is uncommon, yet problematic, among schizophrenia patients. The complex effects of clinical, interpersonal, and social-environmental risk factors for violence in this population are poorly understood. OBJECTIVE: To examine the pre ... Full text Link to item Cite

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

Journal Article Am J Psychiatry · April 2006 OBJECTIVE: When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine. In this study, the authors compared switching to clozapine with switc ... Full text Link to item Cite

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.

Journal Article Am J Psychiatry · April 2006 BACKGROUND: In the treatment of schizophrenia, changing antipsychotics is common when one treatment is suboptimally effective, but the relative effectiveness of drugs used in this strategy is unknown. This randomized, double-blind study compared olanzapine ... Full text Link to item Cite

Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.

Journal Article J Nerv Ment Dis · March 2006 This study examined baseline correlates of substance use in the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness project. Approximately 60% of the sample was found to use substances, including 37% with current evidence of substance use diso ... Full text Link to item Cite

Dr. Lieberman and Colleagues reply [17]

Journal Article American Journal of Psychiatry · March 1, 2006 Cite

Barriers to employment for people with schizophrenia.

Journal Article Am J Psychiatry · March 2006 OBJECTIVE: There is growing interest in identifying and surmounting barriers to employment for people with schizophrenia. The authors examined factors associated with participation in competitive employment or other vocational activities in a large group o ... Full text Link to item Cite

Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.

Journal Article Schizophr Res · March 2006 BACKGROUND: Many patients recovering from a first psychotic episode will discontinue medication against medical advice, even before a 1-year treatment course is completed. Factors associated with treatment adherence in patients with chronic schizophrenia i ... Full text Link to item Cite

Striatal dopamine D2/D3 receptor availability in male smokers.

Journal Article Psychiatry Res · January 30, 2006 It has been reported that the activation of the nicotine receptor evokes central endogenous dopamine release. However, whether smoking affects striatal dopamine D(2)/D(3) availability over the long run has not been well established in vivo. Fifteen male sm ... Full text Link to item Cite

Risks versus benefits of different types of long-acting injectable antipsychotics.

Journal Article J Clin Psychiatry · 2006 Since their introduction into clinical practice in the early 1960s, long-acting depot antipsychotics have been widely used as maintenance therapy for patients with schizophrenia. The improved pharmacokinetics of injectable long-acting antipsychotic therapi ... Link to item Cite

Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

Journal Article Schizophr Res · December 1, 2005 OBJECTIVE: To examine the clinical characteristics of individuals with schizophrenia that develop tardive dyskinesia (TD) associated with antipsychotic treatment. METHODS: Baseline data on 1460 patients with schizophrenia were collected as part of the Clin ... Full text Link to item Cite

Measuring outcome priorities and preferences in people with schizophrenia.

Journal Article Br J Psychiatry · December 2005 BACKGROUND: Measures have not taken account of the relative importance patients place on various outcomes. AIMS: To construct and evaluate a multidimensional, preference-weighted mental health index. METHOD: Each of over 1200 patients identified the relati ... Full text Link to item Cite

Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial.

Journal Article Schizophr Res · December 1, 2005 OBJECTIVE: Uncertainty regarding the degree to which persons with schizophrenia may lack decision-making capacity, and what the predictors of capacity may be led us to examine the relationship between psychopathology, neurocognitive functioning, and decisi ... Full text Link to item Cite

The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

Journal Article Schizophr Res · December 1, 2005 UNLABELLED: The metabolic syndrome (MS) is highly prevalent among patients with schizophrenia (current estimates 35-40%), yet no data exist on the correlation of this diagnosis with illness severity, neurocognitive or quality of life measures in this popul ... Full text Link to item Cite

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

Journal Article Schizophr Res · December 1, 2005 UNLABELLED: One important risk factor for cardiovascular disease is the metabolic syndrome (MS), yet limited data exist on its prevalence in US patients with schizophrenia. METHODS: Using baseline data from the Clinical Antipsychotic Trials of Intervention ... Full text Link to item Cite

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.

Journal Article Br J Psychiatry · December 2005 BACKGROUND: Substantial weight gain is common with many atypical antipsychotics. AIMS: To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or ... Full text Link to item Cite

Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.

Journal Article Schizophr Res · October 15, 2005 OBJECTIVES: Schizophrenia causes significant impairments of quality of life. As treatment approaches have advanced, more attention has been given to re-integrating patients into their psychosocial environments, rather than simply monitoring psychotic sympt ... Full text Link to item Cite

Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia.

Journal Article Eur Neuropsychopharmacol · October 2005 G-proteins are composed of alpha, beta and gamma subunits. Once activated, these subunits play a major role in the conversion of external receptor activation into intracellular signals. The functional C825T polymorphism of the beta3 subunit gene (GNB3) has ... Full text Link to item Cite

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Journal Article N Engl J Med · September 22, 2005 BACKGROUND: The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antip ... Full text Link to item Cite

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.

Journal Article Neurosci Lett · May 6, 2005 The synaptosomal-associated protein of 25 kDa (SNAP-25) is an essential component of the core complex that mediates presynaptic vesicle trafficking. Thus, SNAP-25 is directly involved in the release of neurotransmitters. Quantitative alterations of SNAP-25 ... Full text Link to item Cite

Aripiprazole: pharmacology, efficacy, safety and tolerability.

Journal Article Expert Rev Neurother · May 2005 Aripiprazole is a recently released antipsychotic medication which differs from other atypical antipsychotic agents by its partial agonist activity at postsynaptic D2 receptors. It is administered orally and is distinguished by a long elimination phase hal ... Full text Link to item Cite

Antipsychotic drug effects on brain morphology in first-episode psychosis.

Journal Article Arch Gen Psychiatry · April 2005 BACKGROUND: Pathomorphologic brain changes occurring as early as first-episode schizophrenia have been extensively described. Longitudinal studies have demonstrated that these changes may be progressive and associated with clinical outcome. This raises the ... Full text Link to item Cite

Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment.

Journal Article Pharmacol Res · April 2005 Neurocognitive deficits are recognized as a cardinal feature of schizophrenia. Atypical antipsychotics have high affinity for many neurotransmitter receptors. Among these receptors, antipsychotics are antagonists of adrenoceptors, and this pharmacological ... Full text Link to item Cite

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

Journal Article Schizophrenia Research · 2005 Objective: Standardized mortality rates are elevated in schizophrenia compared to the general population. The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, des ... Full text Cite

Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation [3]

Journal Article Schizophrenia Research · 2005 Full text Cite

Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia.

Journal Article Schizophr Res · January 1, 2005 Maintenance treatment regimens for patients with schizophrenia are often suboptimal. Partial adherence and outright noncompliance are associated with symptom recurrence and increased likelihood of rehospitalization. Long-acting conventional neuroleptics ha ... Full text Link to item Cite

Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.

Journal Article J Psychiatr Res · January 2005 Positive psychotic symptoms, such as threat/"control-override" delusions or command hallucinations, have been related to aggression in patients with schizophrenia. However, retrospective data collection has hampered evaluation of the direct influence of ps ... Full text Link to item Cite

Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.

Journal Article Br J Psychiatry · July 2004 BACKGROUND: Duration of untreated psychosis (DUP) may contribute to the observed heterogeneity of the treatment response in first-episode schizophrenia. AIMS: To examine the relationship of DUP and premorbid function with clinical outcomes following up to ... Full text Link to item Cite

COMT158 polymorphism and hostility.

Journal Article Am J Med Genet B Neuropsychiatr Genet · May 15, 2004 The main study was designed primarily to compare the clinical effects of four antipsychotics in 157 patients with schizophrenia or schizoaffective disorder. The secondary genetic study, reported here, is based on a subset of 60 patients who consented to ge ... Full text Link to item Cite

Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.

Journal Article J Clin Psychiatry · April 2004 BACKGROUND: There has been considerable support for the observation that atypical antipsychotics have a broader range of therapeutic effects than traditional antipsychotics. We are exploring whether this expanded clinical efficacy can also be seen in patie ... Full text Link to item Cite

A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes.

Journal Article J Clin Psychiatry · April 2004 BACKGROUND: Carbamazepine has been used to treat mania for over 2 decades. Most evaluations of carbamazepine have had important limitations, such as absence of a parallel placebo group, small sample size, or the confounding influence of concomitant treatme ... Full text Link to item Cite

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.

Journal Article J Clin Psychiatry · April 2004 BACKGROUND: The Texas Medication Algorithm Project (TMAP) has been a public-academic collaboration in which guidelines for medication treatment of schizophrenia, bipolar disorder, and major depressive disorder were used in selected public outpatient clinic ... Full text Link to item Cite

Overt Aggression and Psychotic Symptoms in Patients with Schizophrenia Treated with Clozapine, Olanzapine, Risperidone, or Haloperidol

Journal Article Journal of Clinical Psychopharmacology · 2004 The subjects were 157 treatment-resistant inpatients diagnosed with chronic schizophrenia or schizoaffective disorder. They were randomly assigned to treatment with clozapine, olanzapine, risperidone, or haloperidol in a 14-week, double-blind trial. Incide ... Full text Cite

Revised PORT recommendations.

Journal Article Schizophr Bull · 2004 Full text Link to item Cite

Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.

Journal Article J Clin Psychiatry · January 2004 BACKGROUND: Prolactin levels are elevated to varying degrees by antipsychotics. Prolactin elevations may result in sexual and other adverse effects, and they may be related to antipsychotic effects. We used the data collected in a trial of antipsychotics t ... Full text Link to item Cite

Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications.

Journal Article Psychopharmacology (Berl) · September 2003 RATIONALE: The absence of a relationship between cognitive deficit treatment response and positive symptom treatment response is often assumed, and few data have shed light on this issue. Most of these data have been collected using standard neuropsycholog ... Full text Link to item Cite

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

Journal Article Am J Psychiatry · August 2003 OBJECTIVE: Few long-term studies have compared the efficacy and safety of typical and atypical antipsychotic medications directly in patients with a first episode of psychosis who met the criteria for schizophrenia or a related psychotic disorder. This stu ... Full text Link to item Cite

Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia.

Journal Article Schizophr Res · March 1, 2003 We examined the test-retest reliabilities of reported and objective measures of smoking, and the intercorrelations among these measures, in acutely psychotic patients with schizophrenia to determine whether severe psychiatric illness affects the utility of ... Full text Link to item Cite

Substance abuse (including nicotine) in schizophrenic patients

Journal Article Current Opinion in Psychiatry · March 1, 2003 Purpose of review: Comorbid substance-use disorders are present in at least 25% of patients with schizophrenia, and 70-80% of these patients smoke. It is important to understand how substance-use disorders affect outcomes in this already impaired populatio ... Full text Cite

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Journal Article Am J Psychiatry · February 2003 OBJECTIVE: The association of hyperglycemia and hypercholesterolemia with use of atypical antipsychotics has been documented in case reports and uncontrolled studies. The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and ha ... Full text Link to item Cite

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Journal Article Schizophr Bull · 2003 The National Institute of Mental Health initiated the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) program to evaluate the effectiveness of antipsychotic drugs in typical settings and populations so that the study results will be max ... Full text Link to item Cite

Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.

Journal Article Schizophr Bull · 2003 Schizophrenia is a symptomatically heterogeneous disorder characterized by the presence of positive and negative symptoms, and variable impairment in community functioning. Given the diversity of symptom presentations and functioning associated with schizo ... Full text Link to item Cite

Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia.

Journal Article Biol Psychiatry · October 1, 2002 BACKGROUND: Neurocognitive deficits are recognized as a cardinal feature of schizophrenia, but the determinants of these deficits remain unknown. Recent reports have suggested that a functional polymorphism, Val(158)Met in exon III of the catechol-O-methyl ... Full text Link to item Cite

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Journal Article J Clin Psychiatry · October 2002 BACKGROUND: When patients with schizophrenia fail to respond to an atypical antipsychotic, they are sometimes switched to another atypical compound. However, the benefits of such a switch have not been adequately studied. We present an open-label prospecti ... Full text Link to item Cite

Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia.

Journal Article Neuropsychopharmacology · October 2002 We applied nicotine 21 mg and matching placebo transdermal patches to thirty haloperidol-treated patients with schizophrenia who smoked. Clinical assessments of bradykinesia-rigidity were lower during nicotine patch administration than during placebo patch ... Full text Link to item Cite

Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources.

Journal Article Schizophr Res · September 1, 2002 INTRODUCTION: Schizophrenia patients, particularly those with specific types of hallucinations and delusions, may have a deficit in monitoring the generation of thought. This deficit, termed autonoetic agnosia, may result in the conclusion that self-genera ... Full text Link to item Cite

The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder and Tourette's syndrome.

Journal Article Curr Drug Targets CNS Neurol Disord · August 2002 As the prevalence of tobacco use has decreased, it has become clear that individuals with mental illness comprise a substantial portion of the remaining smokers. Seventy to eighty percent of patients with schizophrenia smoke and their smoking is establishe ... Full text Link to item Cite

Antipsychotic-induced weight gain and therapeutic response: a differential association.

Journal Article J Clin Psychopharmacol · June 2002 This study investigated the association between antipsychotic-induced weight gain and therapeutic response to haloperidol and three commonly used atypical neuroleptic medications in schizophrenia and schizoaffective disorder. The subjects were 151 patients ... Full text Link to item Cite

Smoking and psychosis in patients with bipolar I disorder.

Journal Article Compr Psychiatry · 2002 We characterized 67 newly admitted patients in manic or mixed episodes of bipolar I disorder on categorical and continuous measures of smoking and psychosis to test the hypothesis that patients who were smokers would be more likely to demonstrate psychotic ... Full text Link to item Cite

Sensory acuity and reasoning in delusional disorder.

Journal Article Compr Psychiatry · 2002 Systematic research on delusional disorder (DD) is limited. The goal of this study was to assess DD patients in the following areas: sensory capacities, decision-making style, and complex reasoning. Ten DD patients and 10 matched normal controls completed ... Full text Link to item Cite

Comparable dopamine 2 receptor occupancy [10] (multiple letters)

Journal Article American Journal of Psychiatry · 2002 Full text Cite

Galantamine for treatment-resistant schizophrenia [3]

Journal Article American Journal of Psychiatry · 2002 Full text Cite

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

Journal Article American Journal of Psychiatry · 2002 Objective: Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients wh ... Full text Cite

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder

Journal Article American Journal of Psychiatry · 2002 Objective: The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder. Met ... Full text Cite

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.

Journal Article Psychiatr Serv · November 2001 OBJECTIVE: This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol. METHODS: A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment ... Full text Link to item Cite

Insight is greater in mixed than in pure manic episodes of bipolar I disorder.

Journal Article J Nerv Ment Dis · June 2001 Full text Link to item Cite

Mecamylamine increases cigarette smoking in psychiatric patients.

Journal Article J Clin Psychopharmacol · December 2000 Full text Link to item Cite

Drugs of the psychopharmacological revolution in clinical psychiatry.

Journal Article Psychiatr Serv · October 2000 Full text Link to item Cite

Schirophrenia, substance misuse, and smoking

Journal Article Current Opinion in Psychiatry · January 1, 2000 The recent literature suggests that enriched genetic loading for substance use disorders, a desire to relieve the subjective distress associated with schizophrenia and its treatment, and 'therapeutic' effects of nicotine may contribute to the high prevalen ... Full text Cite

The role of insight in the treatment and outcome of bipolar disorder

Journal Article Psychiatric Annals · 2000 Cite

Smoking and therapeutic response to clozapine in patients with schizophrenia.

Journal Article Biol Psychiatry · July 1, 1999 BACKGROUND: Of patients with schizophrenia, 70 to 80% smoke. Nicotine corrects certain information processing and cognitive psychomotor deficits seen in many patients with schizophrenia. Clozapine, but not conventional antipsychotics, has been shown to cor ... Full text Link to item Cite

Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients.

Journal Article The Journal of clinical psychiatry · 1999 BACKGROUND: Achieving therapeutic blood levels of a mood stabilizer as quickly as possible is desirable in patients with acute mania. We examined the feasibility and safety of an accelerated oral loading strategy (divalproex, 30 mg/kg/day, on days 1 and 2, ... Cite

Smoking in first-episode patients with schizophrenia [12]

Journal Article American Journal of Psychiatry · 1999 Cite

New treatment options to improve clinical outcomes

Journal Article Journal of Clinical Psychiatry · 1998 Cite

Clozapine-induced electroencephalogram changes as a function of clozapine serum levels.

Journal Article Biol Psychiatry · July 15, 1997 Specific electroencephalogram (EEG) changes during clozapine therapy were prospectively studied in a cohort of 50 chronic state hospital patients with schizophrenia who were randomly assigned to one of three nonoverlapping clozapine serum level ranges (50- ... Full text Link to item Cite

Guideline series commentary [4] (multiple letters)

Journal Article Journal of Clinical Psychiatry · 1997 Cite

Neurotrophin-3 levels in the cerebrospinal fluid of patients with schizophrenia or medical illness

Journal Article Psychiatry Research · 1997 Neurotrophin-3 (NT-3) may have a potential role in the pathogenesis of schizophrenia, given evidence of abnormal neurodevelopment in schizophrenia, as well as a potential association of an NT-3 gene polymorphism with schizophrenia. Cerebrospinal fluid NT-3 ... Full text Cite

A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal

Journal Article Psychopharmacology · 1997 Treatment of the alcohol withdrawal syndrome is best accomplished using pharmacologic agents that have minimal interaction with alcohol, have limited adverse effects, and are without abuse potential. The partial benzodiazepine receptor agonist beta-carboli ... Full text Cite

A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia.

Journal Article Biol Psychiatry · December 15, 1996 Ten men inpatients who met DSM-III-R criteria for schizophrenia participated. On five occasions at least one week apart, each subject had an intravenous line placed at 0730 after an overnight fast. On each occasion blood samples were drawn at 0800 and hour ... Full text Link to item Cite

Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia.

Journal Article Neuropsychopharmacology · December 1996 Lesioning the ventral hippocampus of neonatal rats has been proposed as an experimental model of schizophrenia. This lesion causes a syndrome of hyperresponsivity to the stimulant effects of amphetamine, impaired grooming and disrupted social interactions, ... Full text Link to item Cite

Nicotine-haloperidol interactions and cognitive performance in schizophrenics.

Journal Article Neuropsychopharmacology · November 1996 Nearly 90% of schizophrenics smoke cigarettes, considerably higher than the general population's rate of 25%. There is some indication that schizophrenics may smoke as a form of self-medication. Nicotine has a variety of pharmacologic effects that may both ... Full text Link to item Cite

Monitoring of clozapine blood levels in the real world [10]

Journal Article Journal of Clinical Psychopharmacology · 1996 Full text Cite

Smoking and schizophrenia

Journal Article Drug Development Research · 1996 Patients with schizophrenia smoke at a higher prevalence rate (80%) than the general population (30%). Those patients with schizophrenia who smoke have an earlier age of onset and may have more refractory psychopathology. Smoking improves sensory gating, s ... Full text Cite

Palinacousis after closed-head injury in a patient with schizophrenia [13]

Journal Article Journal of Clinical Psychopharmacology · 1996 Cite

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

Journal Article Psychopharmacology · 1996 Sertindole is a novel antipsychotic agent with high selectivity for the mesolimbic dopaminergic pathway and nanomolar affinities for dopamine D2, serotonin 5-HT2, and norepinephrine NE(α1) receptors. This 40-day randomized, placebo-controlled, dose-ranging ... Full text Cite

Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges

Journal Article American Journal of Psychiatry · 1996 Objective: This study sought to determine the relationships between serum clozapine levels and therapeutic response. Method: Fifty-six inpatients who met the DSM-III-R criteria for chronic schizophrenia and who had not responded to extended treatment with ... Cite

Common sense, insight, and neuropsychological test performance in schizophrenia patients.

Journal Article Schizophr Bull · 1996 We report an exploratory study examining the interrelationships among common sense, insight into psychosis, and performance on a battery of neuropsychological tests in 32 patients with schizophrenia evaluated at the time of discharge from involuntary hospi ... Full text Link to item Cite

Insight in schizophrenia and mania.

Journal Article J Nerv Ment Dis · December 1995 We administered a series of 12 brief vignettes depicting examples of positive, negative, and manic psychopathology in everyday language to 21 patients with schizophrenia and 20 patients with mania. We asked patients to rate, first, how similar they were to ... Full text Link to item Cite

Haloperidol increases smoking in patients with schizophrenia.

Journal Article Psychopharmacology (Berl) · May 1995 Ten patients with schizophrenia participated in 120-min free-smoking sessions when actively psychotic and free of antipsychotic medications, and again after the initiation of haloperidol treatment. During these free-smoking sessions they had access to ciga ... Full text Link to item Cite

Clozapine decreases smoking in patients with chronic schizophrenia.

Journal Article Biol Psychiatry · April 15, 1995 Full text Link to item Cite

Effects of concomitant risperidone and lithium treatment [1]

Journal Article American Journal of Psychiatry · 1995 Cite

How much haldol D does Larry really need? [5]

Journal Article Journal of Clinical Psychiatry · 1995 Cite

Current concepts in schizophrenia: International symposia report new standards for assessment and treatment. Part I: Pathophysiology research prompts assessment updates

Journal Article Journal of Clinical Psychiatry · 1995 Cite

Pharmacotherapy of impaired affect in recovering schizophrenic patients.

Journal Article Arch Gen Psychiatry · January 1995 BACKGROUND: Prominent and persistent anxiety, depression, and/or negative features characterize a substantial minority of recovered or residually psychotic schizophrenic outpatients and contribute to poor outcome. Because extrapyramidal side effects of typ ... Full text Link to item Cite

Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics [4]

Journal Article Journal of Clinical Psychiatry · 1995 Cite

Efficacy of risperidone on positive features of schizophrenia.

Journal Article J Clin Psychiatry · May 1994 Dopaminergic hyperactivity mediated via D2 receptors is implicated in the etiology of positive symptoms of schizophrenia, but selective D2 antagonists provide imperfect therapy. This article describes a subanalysis of a trial of risperidone, a combined 5-H ... Link to item Cite

A pilot study of a structured interview addressing sexual function in men with schizophrenia.

Journal Article Biol Psychiatry · January 1, 1994 Twenty physically healthy men with schizophrenia responded to a 15-item questionnaire inquiring about their usual and their present (on medications) sexual functioning. Two summary measures of present impairment (the average of items 7-13 that detail the p ... Full text Link to item Cite

Insight about psychosis among outpatients with schizophrenia.

Journal Article Hosp Community Psychiatry · September 1993 Full text Link to item Cite

Use of psychopathology vignettes by patients with schizophrenia or schizoaffective disorder and by mental health professionals to judge patients' insight

Journal Article American Journal of Psychiatry · 1993 Objective: The goal of this study was to clarify more precisely where patients with psychotic disorders and the mental health professionals who care for them disagree regarding whether the patient is ill or needs treatment. Method: The authors prepared bri ... Cite

An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients

Journal Article Psychopharmacology · 1993 Following a 4-7 day drug-free washout period, eight male inpatients took an extended-release (ER) formulation of raclopride. After the initial 8 mg dose on day 1 of the study, repeated plasma samples were collected over the ensuing 36 h. Subsequently, pati ... Full text Cite

Patients' rights.

Journal Article Hosp Community Psychiatry · April 1992 Full text Link to item Cite

Haase hermeneutics, or, the exegesis of the neuroleptic threshold.

Journal Article J Clin Psychopharmacol · February 1992 Link to item Cite

Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

Journal Article Arch Gen Psychiatry · August 1991 After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3.7 +/- 2.3 mg/d) for 2 weeks. Ten respon ... Full text Link to item Cite

Predictors of therapeutic response to haloperidol in acute schizophrenia.

Journal Article Psychopharmacol Bull · 1991 During a study of neuroleptic threshold haloperidol doses as treatment for newly admitted schizophrenic patients, we examined whether variables extracted from patients' clinical histories, the type and severity of patients' psychopathology at baseline, or ... Link to item Cite

Shared features of neuroleptic malignant syndrome and alcohol abuse complications.

Journal Article J Clin Psychiatry · December 1990 Link to item Cite

Hospitalized schizophrenic patient views about seclusion.

Journal Article J Clin Psychiatry · May 1989 Twenty-six of 100 consecutively admitted schizophrenic or schizoaffective patients required seclusion during their hospital stays. Seclusion episodes usually involved involuntarily committed, severely ill patients and occurred early in their hospitalizatio ... Link to item Cite

Insight and the clinical outcome of schizophrenic patients

Journal Article Journal of Nervous and Mental Disease · 1989 At the time of discharge from their index hospitalizations, 52 schizophrenic patients initially admitted for acute psychotic episodes were assessed on an Insight and Treatment Attitudes Questionnaire. When these patients were followed up to 2 1/2 to 3 1/2 ... Cite

The dose-response relationship for memory impairment by anticholinergic drugs

Journal Article Comprehensive Psychiatry · 1989 Twelve stabilized chronic schizophrenic outpatients receiving maintenance treatment with fluphenazine decanoate plus anticholinergic antiparkinsonian drugs underwent two challenge sessions receiving, in random sequence and double-blind, injections of eithe ... Cite

Why must some schizophrenic patients be involuntarily committed? The role of insight

Journal Article Comprehensive Psychiatry · 1989 Twenty-four of 52 (46%) schizophrenic patients hospitalized because of acute psychotic episodes associated with preadmission medication noncompliance required involuntary commitment. Committed patients were rated as significantly more severely ill than vol ... Cite

Insight in schizophrenia. Its relationship to acute psychopathology

Journal Article Journal of Nervous and Mental Disease · 1989 The relationship between insight and acute psychopathology was explored in a group of 52 acutely psychotic, schizophrenic patients. A measure of insight, reflecting patients' recognition of their illness and need for care, was validated against ratings fro ... Cite

Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study

Journal Article Archives of General Psychiatry · 1988 Issues regarding the side effects of antipsychotic medication and the possible contribution of the environment to dose requirements led to a two-year controlled dosage study of maintenance antipsychotic medication and familial environment among recently di ... Cite

Dystonia, neuroleptic dose, and anticholinergic drugs.

Journal Article American Journal of Psychiatry · 1987 Cite

Differential therapeutic response by history during treatment with neuroleptic threshold haloperidol doses.

Journal Article Journal of Clinical Psychopharmacology · 1987 Cite

Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia

Journal Article Clinical Therapeutics · 1987 Anticholinergic drugs have been shown to impair new memory acquisition. In a double-blind study, 22 chronically schizophrenic patients had the anticholinergic drugs that they had been taking to control the extrapyramidal side effects (EPSE) of neuroleptic ... Cite

A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function

Journal Article Journal of Clinical Psychiatry · 1987 Anticholinergic antiparkinson drugs administered orally at standard clinically prescribed doses impaired new memory acquisition and mood in normal volunteer subjects, based on tests of free recall, recognition memory, and time production, self-rating of me ... Cite

Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers

Journal Article American Journal of Psychiatry · 1987 Anticholinergic drugs impair one's ability to learn new material, even at routine clinically used doses. During the trihexyphenidyl phase of this double-blind crossover trial, elderly normal subjects complained of confusion and memory impairment and demons ... Cite

The effects of amantadine vs. trihexyphenidyl on memory in elderly normal volunteers

Journal Article Psychopharmacology Bulletin · 1987 Cite

Neuroleptic dose and the need for prophylactic anticholinergic drugs.

Journal Article Journal of Clinical Psychiatry · 1986 Cite

Rapid shifts in therapeutic and extrapyramidal effects of neuroleptics.

Journal Article The American journal of psychiatry · 1986 Cite

Anticholinergic prophylaxis in young adults treated with neuroleptic drugs

Journal Article Psychopharmacology Bulletin · 1986 Cite

Relief from catatonic immobility can be maintained.

Journal Article Journal of clinical psychopharmacology · 1986 Cite

Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study

Journal Article Journal of Clinical Psychopharmacology · 1986 The daily haloperidol doses of 33 newly admitted, acutely psychotic schizophrenic patients were rapidly adjusted to a point at which slight hypokinesia-rigidity first appeared on clinical examination (the neuroleptic threshold). The mean daily haloperidol ... Cite

The neuroleptic threshold as a marker of minimum effective neuroleptic dose

Journal Article Comprehensive Psychiatry · 1986 The neuroleptic threshold hypothesis states that the first appearance of slight increases in muscle tone during the initiation of neuroleptic treatment heralds the achievement of neuroleptic levels in the brain which are biologically significant and capabl ... Cite

Diazepam for catatonia

Journal Article American Journal of Psychiatry · 1984 Intravenous diazepam rapidly relieved catatonic immobility in two schizophrenic patients, and oral diazepam maintained this therapeutic effect. Diazepam may be an immediately available and effective treatment for some patients with life-threatening cataton ... Cite

Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenic patients

Journal Article Journal of Nervous and Mental Disease · 1984 Two subgroups of relapsed and rehospitalized schizophrenic patients were separated on the basis of preadmission compliance or noncompliance with prescribed antipsychotic medications. Noncompliant patients had a gradual onset of episode with prominent psych ... Cite

The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs

Journal Article Journal of Clinical Psychopharmacology · 1983 Cite

Chronic schizophrenic women's attitudes toward sex, pregnancy, birth control, and childrearing

Journal Article Hospital and Community Psychiatry · 1983 Interviews with 23 chronically institutionalized, schizophrenic women living on a chronic care unit and ranging in age from 20-58 years were interviewed to provide initial systematic data about the attitudes of chronic schizophrenic women toward sex, pregn ... Cite

Bromperidol maintenance in schizophrenia.

Journal Article Pharmacopsychiatria · 1982 Twenty-three patients who completed a four-week, double-blind, clinical trial of bromperidol versus haloperidol were treated with bromperidol for eight additional weeks in a continuation study. Over 87 percent of patients maintained their improved status o ... Cite

A collaborative study of a new antidepressant, viloxazine, in neurotic and endogenous depressives

Journal Article International Pharmacopsychiatry · 1982 In a multicenter series of trials, viloxazine was compared with imipramine, amitriptyline, doxepin and placebo in 123 neurotic and endogenous depressive inpatients and outpatients. While significant period effects reflecting improvement were obtained on th ... Cite

Sociocultural identity and psychogenic psychosis.

Journal Article Papua and New Guinea Medical Journal · 1982 Cite

Viloxazine HCl in the treatment of endogenous depression: A standard (imipramine) controlled clinical study

Journal Article Journal of Clinical Psychiatry · 1982 In a four week, double-blind clinical trial, 20 patients with endogenous depression were randomly assigned to treatment with either viloxazine or imipramine. Statistically significant improvement was observed on the Hamilton Psychiatric Rating Scales for D ... Cite

Measuring chronic schizophrenic patients' attitudes toward their illness and treatment

Journal Article Hospital and Community Psychiatry · 1981 The right to refuse medication is a legal right now being extended by federal courts to many voluntary and involuntary mental patients. However, little is known of the insight that chronically ill mental patients bring to the decision of whether or not to ... Cite

Organic brain syndromes in DSM-III.

Journal Article American Journal of Psychiatry · 1981 Cite

Organic brain syndromes

Journal Article Annals of Internal Medicine · 1981 Awareness of the medical disorders that frequently present with neuropsychiatric signs and symptoms and careful attention to a basic medical evaluation in every 'psychiatric' patient will obviate referral of such patients to mental health facilities where ... Cite

A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients

Journal Article Pharmacopsychiatria · 1981 Cite

Amoxapine: A review of literature

Journal Article International Pharmacopsychiatry · 1980 Amoxapine, a new antidepressant, is a tricyclic dibenzoxazepine compound, the demethylated metabolite of the neuroleptic loxapine. In animal pharmacological studies, amoxapine has shown striking similarities to imipramine. In contrast to the prototype anti ... Cite

Viloxazine in the treatment of depressive neurosis: A placebo and standard (imipramine) controlled clinical study

Journal Article International Pharmacopsychiatry · 1980 In a 4-week double-blind trial, 33 patients with depressive neurosis were randomly assigned to either viloxazine, imipramine or placebo. Statistically significant improvement was observed in all treatment groups. Imipramine exhibited significant improvemen ... Cite

A double-blind comparison of three dosages of flutroline (CP-36,584) in the treatment of schizophrenia

Journal Article International Pharmacopsychiatry · 1980 Therapeutic and adverse effects of three dosages (1, 20 and 100 mg daily) of flutroline, a new γ-carboline with a preclinical pharmacological profile similar to active neuroleptic agents, were compared in a double-blind clinical trial in 25 newly-admitted ... Cite

Viloxazine: A review of the literature

Journal Article International Pharmacopsychiatry · 1980 In animal pharmacological studies viloxazine has shown similarities to imipramine. The antidepressant effects of the substance were independently recognized in seven uncontrolled clinical trials and verified in 11 published standard controlled clinical stu ... Cite

Viloxazine in the treatmentof depressive neurosis: A controlled clinical study with doxepin and placebo

Journal Article British Journal of Psychiatry · 1980 In a four-week, double-blind, clinical trial thirty-one patients with depressive neurosis were treated with viloxazine, doxepin, or placebo. There were no differences among the three groups in therapeutic effects. Many depressed out-patients improve on pla ... Cite

Case studies in neuropsychiatry II: Conversion pseudodementia

Journal Article Journal of Clinical Psychiatry · 1979 A patient is described who experienced pseudodementia as a conversion reaction. The patient was considered to be demented originally because of the evidence for profound cognitive impairment elicited on mental state examination. Careful analysis of the pat ... Cite

Psychiatric consultations

Journal Article Southern Medical Journal · 1978 Cite